SCHEMBL1180310

SCHEMBL1180310

Cc1cc(-c2nc(-c3cc(C)nc(N(C)CC(C)C)n3)no2)cc(C)n1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 10/20 0.40
S1PR5 Q9H228 1/20 0.40
GRM5 P41594 4/20 0.36
TP53 P04637 3/20 0.36
PKM P14618 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ESR1 P03372 1/20 0.36
NPC1 O15118 3/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
S1PR3 Q99500 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
CRHR1 P34998 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179888 0.90 ESR1 (0.36) S1PR1S1PR5TP53ESR1NPC1
SCHEMBL1178761 0.81 S1PR1 (0.52) S1PR1S1PR5GRM5TP53PKM
SCHEMBL1179699 0.80 ESR1 (0.37) S1PR1S1PR5ESR1S1PR3
SCHEMBL1180194 0.80 CRHR1 (0.37) S1PR1S1PR5GRM5TP53PKM
SCHEMBL1179422 0.79 GRM5 (0.39) S1PR1S1PR5GRM5TP53PKM
SCHEMBL1179764 0.75 S1PR1 (0.34) S1PR1GRM5TP53NPC1MAPT
SCHEMBL1179054 0.75 GRM5 (0.36) S1PR1S1PR5GRM5TP53PKM
SCHEMBL12870986 0.74 ESR1 (0.46) ESR1ALDH1A1SMN1; SMN2CRHR1
SCHEMBL1179102 0.73 S1PR1 (0.33) S1PR1NPC1MAPTRAB9AALDH1A1
SCHEMBL1179359 0.73 S1PR1 (0.36) S1PR1S1PR5GRM5TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US claimed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP claimed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO claimed
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-24 US disclosed
EP-2262800-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109907-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046170-A1 NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES TYMP, DPYD, ENTPD5 S1PR1 766/4885S1PR5 739/4885GRM5 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.